{"id":7829,"date":"2021-06-24T05:26:21","date_gmt":"2021-06-24T05:26:21","guid":{"rendered":"https:\/\/www.nicox.com\/nicox-presentation-au-world-glaucoma-e-congress-2021-des-resultats-de-letude-de-phase-2-dolomites-sur-le-ncx-470-chez-des-patients-atteints-de-glaucome\/"},"modified":"2021-06-24T05:26:21","modified_gmt":"2021-06-24T05:26:21","slug":"nicox-presentation-au-world-glaucoma-e-congress-2021-des-resultats-de-letude-de-phase-2-dolomites-sur-le-ncx-470-chez-des-patients-atteints-de-glaucome","status":"publish","type":"post","link":"https:\/\/www.nicox.com\/fr\/nicox-presentation-au-world-glaucoma-e-congress-2021-des-resultats-de-letude-de-phase-2-dolomites-sur-le-ncx-470-chez-des-patients-atteints-de-glaucome\/","title":{"rendered":"Nicox\u00a0: Pr\u00e9sentation au World Glaucoma E-Congress 2021 des r\u00e9sultats de l\u2019\u00e9tude de phase 2 Dolomites sur le NCX 470 chez des patients atteints de glaucome"},"content":{"rendered":"<p>Sophia Antipolis, France<\/p>\n<p><strong>Nicox SA<\/strong> (Euronext Paris : FR0013018124, COX, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce que <strong>les r\u00e9sultats de l\u2019\u00e9tude clinique de phase 2 Dolomites sur le NCX 470 chez des patients atteints de glaucome \u00e0 angle ouvert ou d\u2019hypertension oculaire seront pr\u00e9sent\u00e9s<\/strong> par le Dr. David Wirta, Medical Director \u00e0 la Eye Research Foundation (Newport Beach, Californie, Etats-Unis) <strong>au World Glaucoma E-Congress 2021<\/strong> qui se tiendra du 30 juin au 3 juillet 2021. Le Dr. Wirta est l\u2019un des investigateurs cliniques de l\u2019\u00e9tude Dolomites.<\/p>\n<p>La pr\u00e9sentation du Dr Wirta sera disponible \u00e0 partir du 30 juin 2021 sur le site internet du World Glaucoma E-Congress via un lien d\u00e9di\u00e9 aux E-posters.<\/p>\n<p>Principal candidat m\u00e9dicament en d\u00e9veloppement clinique de Nicox, le NCX 470 est un nouvel analogue de prostaglandine donneur d\u2019oxyde nitrique (NO) \u00e0 un stade avanc\u00e9 de d\u00e9veloppement clinique pour la r\u00e9duction de la pression intraoculaire chez les patients atteints de glaucome \u00e0 angle ouvert ou d\u2019hypertension oculaire.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sophia Antipolis, France Nicox SA (Euronext Paris : FR0013018124, COX, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce que les r\u00e9sultats de l\u2019\u00e9tude clinique de phase 2 Dolomites sur le NCX 470 chez des patients atteints de glaucome \u00e0 angle ouvert ou d\u2019hypertension oculaire seront pr\u00e9sent\u00e9s par le Dr. David Wirta, Medical Director \u00e0 la [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[32,16],"tags":[],"class_list":["post-7829","post","type-post","status-publish","format-standard","hentry","category-actualites","category-actualites-et-media"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nicox\u00a0: Pr\u00e9sentation au World Glaucoma E-Congress 2021 des r\u00e9sultats de l\u2019\u00e9tude de phase 2 Dolomites sur le NCX 470 chez des patients atteints de glaucome - Nicox<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.nicox.com\/fr\/nicox-presentation-au-world-glaucoma-e-congress-2021-des-resultats-de-letude-de-phase-2-dolomites-sur-le-ncx-470-chez-des-patients-atteints-de-glaucome\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nicox\u00a0: Pr\u00e9sentation au World Glaucoma E-Congress 2021 des r\u00e9sultats de l\u2019\u00e9tude de phase 2 Dolomites sur le NCX 470 chez des patients atteints de glaucome - Nicox\" \/>\n<meta property=\"og:description\" content=\"Sophia Antipolis, France Nicox SA (Euronext Paris : FR0013018124, COX, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce que les r\u00e9sultats de l\u2019\u00e9tude clinique de phase 2 Dolomites sur le NCX 470 chez des patients atteints de glaucome \u00e0 angle ouvert ou d\u2019hypertension oculaire seront pr\u00e9sent\u00e9s par le Dr. David Wirta, Medical Director \u00e0 la [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.nicox.com\/fr\/nicox-presentation-au-world-glaucoma-e-congress-2021-des-resultats-de-letude-de-phase-2-dolomites-sur-le-ncx-470-chez-des-patients-atteints-de-glaucome\/\" \/>\n<meta property=\"og:site_name\" content=\"Nicox\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-24T05:26:21+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-presentation-au-world-glaucoma-e-congress-2021-des-resultats-de-letude-de-phase-2-dolomites-sur-le-ncx-470-chez-des-patients-atteints-de-glaucome\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-presentation-au-world-glaucoma-e-congress-2021-des-resultats-de-letude-de-phase-2-dolomites-sur-le-ncx-470-chez-des-patients-atteints-de-glaucome\\\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Nicox\u00a0: Pr\u00e9sentation au World Glaucoma E-Congress 2021 des r\u00e9sultats de l\u2019\u00e9tude de phase 2 Dolomites sur le NCX 470 chez des patients atteints de glaucome\",\"datePublished\":\"2021-06-24T05:26:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-presentation-au-world-glaucoma-e-congress-2021-des-resultats-de-letude-de-phase-2-dolomites-sur-le-ncx-470-chez-des-patients-atteints-de-glaucome\\\/\"},\"wordCount\":190,\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"articleSection\":[\"Actualit\u00e9s\",\"Actualit\u00e9s et M\u00e9dia\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-presentation-au-world-glaucoma-e-congress-2021-des-resultats-de-letude-de-phase-2-dolomites-sur-le-ncx-470-chez-des-patients-atteints-de-glaucome\\\/\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-presentation-au-world-glaucoma-e-congress-2021-des-resultats-de-letude-de-phase-2-dolomites-sur-le-ncx-470-chez-des-patients-atteints-de-glaucome\\\/\",\"name\":\"Nicox\u00a0: Pr\u00e9sentation au World Glaucoma E-Congress 2021 des r\u00e9sultats de l\u2019\u00e9tude de phase 2 Dolomites sur le NCX 470 chez des patients atteints de glaucome - Nicox\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\"},\"datePublished\":\"2021-06-24T05:26:21+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-presentation-au-world-glaucoma-e-congress-2021-des-resultats-de-letude-de-phase-2-dolomites-sur-le-ncx-470-chez-des-patients-atteints-de-glaucome\\\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"name\":\"Nicox\",\"description\":\"Visible Science\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\",\"name\":\"Nicox\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Nicox\"},\"image\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nicox\u00a0: Pr\u00e9sentation au World Glaucoma E-Congress 2021 des r\u00e9sultats de l\u2019\u00e9tude de phase 2 Dolomites sur le NCX 470 chez des patients atteints de glaucome - Nicox","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.nicox.com\/fr\/nicox-presentation-au-world-glaucoma-e-congress-2021-des-resultats-de-letude-de-phase-2-dolomites-sur-le-ncx-470-chez-des-patients-atteints-de-glaucome\/","og_locale":"fr_FR","og_type":"article","og_title":"Nicox\u00a0: Pr\u00e9sentation au World Glaucoma E-Congress 2021 des r\u00e9sultats de l\u2019\u00e9tude de phase 2 Dolomites sur le NCX 470 chez des patients atteints de glaucome - Nicox","og_description":"Sophia Antipolis, France Nicox SA (Euronext Paris : FR0013018124, COX, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce que les r\u00e9sultats de l\u2019\u00e9tude clinique de phase 2 Dolomites sur le NCX 470 chez des patients atteints de glaucome \u00e0 angle ouvert ou d\u2019hypertension oculaire seront pr\u00e9sent\u00e9s par le Dr. David Wirta, Medical Director \u00e0 la [&hellip;]","og_url":"https:\/\/www.nicox.com\/fr\/nicox-presentation-au-world-glaucoma-e-congress-2021-des-resultats-de-letude-de-phase-2-dolomites-sur-le-ncx-470-chez-des-patients-atteints-de-glaucome\/","og_site_name":"Nicox","article_published_time":"2021-06-24T05:26:21+00:00","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.nicox.com\/fr\/nicox-presentation-au-world-glaucoma-e-congress-2021-des-resultats-de-letude-de-phase-2-dolomites-sur-le-ncx-470-chez-des-patients-atteints-de-glaucome\/#article","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/nicox-presentation-au-world-glaucoma-e-congress-2021-des-resultats-de-letude-de-phase-2-dolomites-sur-le-ncx-470-chez-des-patients-atteints-de-glaucome\/"},"author":{"name":"","@id":""},"headline":"Nicox\u00a0: Pr\u00e9sentation au World Glaucoma E-Congress 2021 des r\u00e9sultats de l\u2019\u00e9tude de phase 2 Dolomites sur le NCX 470 chez des patients atteints de glaucome","datePublished":"2021-06-24T05:26:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.nicox.com\/fr\/nicox-presentation-au-world-glaucoma-e-congress-2021-des-resultats-de-letude-de-phase-2-dolomites-sur-le-ncx-470-chez-des-patients-atteints-de-glaucome\/"},"wordCount":190,"publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"articleSection":["Actualit\u00e9s","Actualit\u00e9s et M\u00e9dia"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.nicox.com\/fr\/nicox-presentation-au-world-glaucoma-e-congress-2021-des-resultats-de-letude-de-phase-2-dolomites-sur-le-ncx-470-chez-des-patients-atteints-de-glaucome\/","url":"https:\/\/www.nicox.com\/fr\/nicox-presentation-au-world-glaucoma-e-congress-2021-des-resultats-de-letude-de-phase-2-dolomites-sur-le-ncx-470-chez-des-patients-atteints-de-glaucome\/","name":"Nicox\u00a0: Pr\u00e9sentation au World Glaucoma E-Congress 2021 des r\u00e9sultats de l\u2019\u00e9tude de phase 2 Dolomites sur le NCX 470 chez des patients atteints de glaucome - Nicox","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/#website"},"datePublished":"2021-06-24T05:26:21+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.nicox.com\/fr\/nicox-presentation-au-world-glaucoma-e-congress-2021-des-resultats-de-letude-de-phase-2-dolomites-sur-le-ncx-470-chez-des-patients-atteints-de-glaucome\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.nicox.com\/fr\/#website","url":"https:\/\/www.nicox.com\/fr\/","name":"Nicox","description":"Visible Science","publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.nicox.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.nicox.com\/fr\/#organization","name":"Nicox","url":"https:\/\/www.nicox.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Nicox"},"image":{"@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":""}]}},"_links":{"self":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/7829","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/comments?post=7829"}],"version-history":[{"count":0,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/7829\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/media?parent=7829"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/categories?post=7829"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/tags?post=7829"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}